FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202023953> ?p ?o ?g. }

• W3202023953 endingPage "A7" @default.
• W3202023953 startingPage "A6" @default.
• W3202023953 abstract "Background Anti-inflammatory (M2) tumour-associated macrophages (TAMs) exert protumoural roles through angiogenesis, immunosuppression and resistance to therapies. 1 M2 TAMs express the mannose receptor, CD206, 2 excellent marker for targeted therapies. We have previously identified a peptide called mUNO 2 that specifically binds to CD206 on M2 TAMs. Aiming to dissect the role of CD206 high M2 TAMs in the tumour progression and immunosuppression, we depleted them using an mUNO and doxorubicin (Adriamycin®)-containing polymer-drug nanoconjugate (St-PGA-DOX-mUNO, ‘OximUNO’) where the polymer backbone is branched polyglutamic acid (St-PGA). 3 Materials and Methods We compared OximUNO with free DOX and the untargeted nanoconjugate St-PGA-DOX. To study the in vitro cytotoxicity of the nanoconjugates, we used M2 and M1 skewed macrophages derived from human blood buffy coat. To study the in vivo homing of nanoconjugates we used an orthotopic triple negative breast cancer (TNBC, 4T1 cells) model and a TNBC experimental metastases model in immunocompetent mice. For in vivo therapeutic efficacy studies, we used orthotopic and experimental metastases models of TNBC, and administered the compounds intraperitoneally (i.p.). Results In vitro, OximUNO showed 39% higher toxicity to the primary human M2 macrophages than St-PGA-DOX, and 31% lower toxicity to the M1 macrophages than St-PGA-DOX. In vivo, OximUNO showed no change in creatinine or alanine aminotransferase values, indicating no toxic effects to the kidneys or liver. Compared to control St-PGA, i.p.-administered St-PGA-mUNO, showed improved homing to M2 TAMs in both orthotopic and experimental metastases models with low accumulation in the liver. In the orthotopic treatment study, only OximUNO significantly reduced the tumour volume and showed 56% and 38% less lung metastases than DOX and St-PGA-DOX, respectively. Additionally, DOX and St-PGA-DOX produced a significant bodyweight loss whereas OximUNO did not. Importantly, OximUNO treatment resulted in 2-5-fold increase in the ratio of CD8 + /FOXP3 + expression, suggesting a shift in the immune landscape towards an immunostimulatory profile. In the experimental metastases model, OximUNO monotherapy resulted in the highest reduction of lung metastases, and this effect correlated with a significant reduction in CD206 high M2 TAMs; whereas no significant effect on M2 TAMs population was observed with DOX or untargeted nanoconjugate. Conclusions Our data suggests that the elimination of CD206 high M2 TAMs with OximUNO suppresses spontaneous and experimental metastases in safe manner, shifts immune landscape towards immunostimulatory and could therefore be a potential treatment option for TNBC patients. References Hughes R, Qian B-Z, Rowan C, Muthana M, Keklikoglou I, Olson OC, et al . Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 2015; 75 (17):3479–91. Scodeller P, Simón-Gracia L, Kopanchuk S, Tobi A, Kilk K, Säälik P, et al . Precision targeting of tumor macrophages with a CD206 binding peptide. Sci Rep 2017; 7 (1):14655. Duro-Castano A, Nebot VJ, Niño-Pariente A, Armiñán A, Arroyo-Crespo JJ, Paul A, et al . Capturing ‘extraordinary’ soft-assembled charge-like polypeptides as a strategy for nanocarrier design. Adv Mater 2017; 29 (39):1702888. Disclosure Information A. Lepland: None. A. Malfanti: None. U. Haljasorg: None. S. Dordevic: None. L. Salumäe: None. P. Peterson: None. T. Teesalu: None. M.J. Vicent: None. P. Scodeller: None." @default.
• W3202023953 created "2021-10-11" @default.
• W3202023953 creator A5008265360 @default.
• W3202023953 creator A5020277720 @default.
• W3202023953 creator A5034936084 @default.
• W3202023953 creator A5054750107 @default.
• W3202023953 creator A5067888978 @default.
• W3202023953 creator A5073981521 @default.
• W3202023953 creator A5079758008 @default.
• W3202023953 creator A5081012899 @default.
• W3202023953 creator A5083919487 @default.
• W3202023953 date "2021-10-01" @default.
• W3202023953 modified "2023-09-25" @default.
• W3202023953 title "P01.07 Depletion of CD206high tumour-associated macrophages using a nanoconjugate limits tumour burden & dissemination in metastatic triple negative breast cancer in mice" @default.
• W3202023953 doi "https://doi.org/10.1136/jitc-2021-itoc8.11" @default.
• W3202023953 hasPublicationYear "2021" @default.
• W3202023953 type Work @default.
• W3202023953 sameAs 3202023953 @default.
• W3202023953 citedByCount "0" @default.
• W3202023953 crossrefType "journal-article" @default.
• W3202023953 hasAuthorship W3202023953A5008265360 @default.
• W3202023953 hasAuthorship W3202023953A5020277720 @default.
• W3202023953 hasAuthorship W3202023953A5034936084 @default.
• W3202023953 hasAuthorship W3202023953A5054750107 @default.
• W3202023953 hasAuthorship W3202023953A5067888978 @default.
• W3202023953 hasAuthorship W3202023953A5073981521 @default.
• W3202023953 hasAuthorship W3202023953A5079758008 @default.
• W3202023953 hasAuthorship W3202023953A5081012899 @default.
• W3202023953 hasAuthorship W3202023953A5083919487 @default.
• W3202023953 hasBestOaLocation W32020239531 @default.
• W3202023953 hasConcept C121608353 @default.
• W3202023953 hasConcept C126322002 @default.
• W3202023953 hasConcept C150903083 @default.
• W3202023953 hasConcept C185592680 @default.
• W3202023953 hasConcept C202751555 @default.
• W3202023953 hasConcept C207001950 @default.
• W3202023953 hasConcept C2776694085 @default.
• W3202023953 hasConcept C2779013556 @default.
• W3202023953 hasConcept C2780110267 @default.
• W3202023953 hasConcept C2780394083 @default.
• W3202023953 hasConcept C2781303535 @default.
• W3202023953 hasConcept C502942594 @default.
• W3202023953 hasConcept C530470458 @default.
• W3202023953 hasConcept C55493867 @default.
• W3202023953 hasConcept C71924100 @default.
• W3202023953 hasConcept C86803240 @default.
• W3202023953 hasConcept C98274493 @default.
• W3202023953 hasConceptScore W3202023953C121608353 @default.
• W3202023953 hasConceptScore W3202023953C126322002 @default.
• W3202023953 hasConceptScore W3202023953C150903083 @default.
• W3202023953 hasConceptScore W3202023953C185592680 @default.
• W3202023953 hasConceptScore W3202023953C202751555 @default.
• W3202023953 hasConceptScore W3202023953C207001950 @default.
• W3202023953 hasConceptScore W3202023953C2776694085 @default.
• W3202023953 hasConceptScore W3202023953C2779013556 @default.
• W3202023953 hasConceptScore W3202023953C2780110267 @default.
• W3202023953 hasConceptScore W3202023953C2780394083 @default.
• W3202023953 hasConceptScore W3202023953C2781303535 @default.
• W3202023953 hasConceptScore W3202023953C502942594 @default.
• W3202023953 hasConceptScore W3202023953C530470458 @default.
• W3202023953 hasConceptScore W3202023953C55493867 @default.
• W3202023953 hasConceptScore W3202023953C71924100 @default.
• W3202023953 hasConceptScore W3202023953C86803240 @default.
• W3202023953 hasConceptScore W3202023953C98274493 @default.
• W3202023953 hasIssue "Suppl 1" @default.
• W3202023953 hasLocation W32020239531 @default.
• W3202023953 hasOpenAccess W3202023953 @default.
• W3202023953 hasPrimaryLocation W32020239531 @default.
• W3202023953 hasRelatedWork W1966181922 @default.
• W3202023953 hasRelatedWork W1979038925 @default.
• W3202023953 hasRelatedWork W2052185098 @default.
• W3202023953 hasRelatedWork W2190794004 @default.
• W3202023953 hasRelatedWork W2358524972 @default.
• W3202023953 hasRelatedWork W2368257851 @default.
• W3202023953 hasRelatedWork W2416964709 @default.
• W3202023953 hasRelatedWork W3180129935 @default.
• W3202023953 hasRelatedWork W4206587034 @default.
• W3202023953 hasRelatedWork W4283771460 @default.
• W3202023953 hasVolume "9" @default.
• W3202023953 isParatext "false" @default.
• W3202023953 isRetracted "false" @default.
• W3202023953 magId "3202023953" @default.
• W3202023953 workType "article" @default.